Notice for selumetinib (AstraZeneca Pty Ltd)
Active ingredients
selumetinib
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Hard capsule
Indication
Treatment of Neurofibromatosis Type 1
Therapeutic area
Oncology